english.prescrire.org > Spotlight > Archives : 2026 > Fezolinetant (Veoza°) for menopause-related hot flushes

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

Fezolinetant (Veoza°) for menopause-related hot flushes

 Marketing Authorisations  Fezolinetant has been authorised in the European Union to treat moderate to severe vasomotor symptoms associated with menopause. In this situation, how effective is fezolinetant against hot flushes compared with menopausal hormone therapy? Is it effective in women who cannot receive menopausal hormone therapy? Do symptoms rebound when fezolinetant is discontinued? And what are its adverse effects? 
Full article available for download by subscribers

 ©Prescrire 1 January 2026

Source: "Fezolinetant (Veoza°) for menopause-related hot flushes" Prescrire Int 2026; 35 (277): 5-8. Subscribers only.

Filet

Enjoy full access to Prescrire International, and support independent information